Sooners may soon be vaccinated against infection, a common sexually transmitted disease that can lead to infertility, the results of preliminary research conducted to develop the vaccine are encouraging, the study said on Tuesday and quoted by AFP.
Published in The Lancet Infectious Disease, the study shows that the vaccine being developed is "safe and capable of eliciting an immune response".
But despite the "encouraging" results, scientists are still in a preliminary phase, requiring more research "to find out whether the activated immune response effectively protects against chlamydia infection," according to the study.
This would be the first vaccine made against this bacterial infection and will be tested in a clinical trial in the next phase.
Annually, 131 million people worldwide contract Chlamydia, according to estimates by the World Health Organization (WHO).
However, these estimates may be far from reality, as about 70% of infected women show no symptoms and are unaware that they have contracted this infection with sexually transmitted infections.
Chlamydia is more common in women between the ages of 18 and 25 than men of the same age. In women, the disease can lead to serious complications, including pelvic inflammatory disease, intrauterine pregnancy, and even infertility.
In addition, it increases the risk of contracting other sexually transmitted diseases, such as gonorrhea or HIV infection, the AIDS virus.
Chlamydia infection can be cured by antibiotic treatment.
But "given the impact of this epidemic on women, reproductive health and children in the event of transmission (…), the need for a vaccine is real," said one of the study's authors, Professor Peter Andersen of the Danish research institute Statsens. "Serum Institute.
The researchers conducted a study of 35 women who were not infected with chlamydia, using two different vaccine formulations. Fifteen of them received one of these formulations (given five times by hand injections, then nasal spray), and another fifteen received a second formulation, five times, and the last five received placebo.
Both vaccine formulations elicited an immune response as manifested by antibody production in all tested women.
However, the performance of the first formulation was improved because it enabled the production of several antibodies. Therefore, she was selected for further research.
"Although it takes many years of research, we intend to move on to the next phase, a second phase clinical trial," explained researcher Jelena B. eluel from the team of scientists who published the study, quoted by Agerpress.